54 results
P
BCG vaccination, vitamin D supplementation, altitude, HIV-negativity/therapy, tuberculosis disease, parasitism, latent tuberculosis infection
I/C
WBMGA, correlates of tuberculosis susceptibility
O
associations with tuberculosis susceptibility
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
patients with tuberculosis
I/C
comparison with individuals without tuberculosis, individuals without tuberculosis
O
risk of coronary heart disease
P
diabetic patients with tuberculosis, nondiabetic patients with tuberculosis
I/C
rifampicin, diabetic vs. nondiabetic patients with tuberculosis
O
pharmacokinetic parameters of rifampicin
P
people being investigated for tuberculosis
I/C
Xpert MTB/RIF, smear microscopy
O
mortality, proportion of participants starting tuberculosis treatment who had a successful treatment outcome, proportion of participants who were treated for tuberculosis, proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment, proportion of treated participants who had bacteriological confirmation
P
Tuberculosis-exposed children
I/C
Contact investigations and preventive therapy, Children with negative TB infection results
O
Development of tuberculosis
P
tuberculosis, smokers
I/C
smoking cessation, no smoking
O
reduced risk of tuberculosis recurrence
P
prisoners
I/C
tuberculosis prevention and control strategies, no intervention
O
high prevalence of tuberculosis
P
patients with tuberculosis
I/C
micronutrient intervention during tuberculosis treatment, control group (or placebo group)
O
sputum conversion
P
diabetic tuberculosis patients, non-diabetic tuberculosis patients
I/C
rifampicin's plasma concentration, low rifampicin's plasma concentration
O
37% attributed risk fraction of diabetes mellitus